Puma Biotechnology Inc (PBYI) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access PBYI Annual Balance Sheets →
The balance sheet data below highlights changes in Puma Biotechnology Inc's financial position over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent86.80
Marketable Securities, Current SH57.37
Cash & Short-term Investments143.00
Accounts receivable34.06
Inventories13.32
Other Current Assets0.00
Prepaid Expense, Current AS3.59
Total Current Assets145.07
Equipment/Property/Plant Net3.01
Intangible Assets36.52
Deferred, Prepaid and Other Assets, Noncurrent6.38
Other Assets, Noncurrent1.76
Total Assets192.74
Liabilities
Accounts Payable, Current AC3.11
Accrued Liabilities, Current AC45.13
Long-term Debt, Current Maturities LO0.00
Other Liabilities, Current1.59
Total Current Liabilities49.83
Long-term debt0.00
Total Long-term Debt0.00
Other liabilities, Noncurrent4.37
Total Liabilities54.19
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,417.92
Retained Earnings / Accumulated Deficit-1,279.34
Accumulated Other Comprehensive Income-0.05
Other Equity-0.05
Common Stockholder's Equity138.54
Total Stockholder's Equity138.54
Liabilities & Stockholder's Equity192.74
4 historic quarters locked

Sign in to unlock the full Puma Biotechnology Inc balance sheet history.

About Puma Biotechnology Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-26-026311

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.